pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 26·1 min read
save

Many post-Dobbs abortion concerns have not materialized, says expert

Aug 26, 2026·read at STAT ↗Neutral

David N. Hackney, a professor of reproductive biology and division chief of maternal‑fetal medicine, reflects on the four years since the Supreme Court overturned Roe v. Wade. He notes that several of the dire predictions made at the time have not come to pass.

He had anticipated that abortion rates would drop sharply, that infant and maternal mortality would worsen, and that physicians in heavily restricted states would relocate. While those expectations were logical, they required extensive data to confirm.

Recent observations, according to Hackney, show that many of those worst‑case outcomes have not materialized. He argues that advocates should ground their arguments in fundamental freedoms and values rather than relying solely on statistical forecasts.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Many post-Dobbs abortion fears have not come to pass. What does that mean for advocates?”

read at STAT ↗
1,140 words · retrieved Aug 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Case Western Reserve University2
drugs
MIFEPRISTONE
topics
Oncology2Breast Cancer

related stories

  • May 15Opinion: Telehealth abortion with mifepristone continues, with backup plans still in placeSTAT
  • May 5Opinion: The ‘brain drain’ narrative about health professionals misses half of the storySTAT
  • May 4UCB to acquire maker of antibody treatments for autoimmune diseasesSTAT
  • May 6Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive
  • May 6Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive